.
Rheumatic heart disease has long been considered the main cause of primary (or organic) MVD 7 , but the incidence of this aetiology has dramatically declined over the past 5 decades 8 . However, no concomitant decline in the prevalence of all valvular heart disease has occurred, because degenerative valve disease has become more prevalent in developed countries owing to ageing of the population 8 . In the EuroHeart survey conducted in 2001, rheumatic heart disease was the most frequent aetiology (51.4%) of MVD, followed by degenerative valve disease (40.6%) 1 . Other, less frequent, causes of primary MVD include endocarditis, thoracic and mediastinal radiation therapy, and the adverse effects of drugs. Even less frequently, connective tissue disorders, and aortic root and myxomatous mitral and tricuspid valve disease linked to genetic syndromes, can be associ ated with MVD 9 . Mitral and tricuspid regurgitation can also develop in the presence of a structurally normal valve owing to malco aptation. These common forms of mitral and tricuspid regurgitation, classified as secondary regurgitation, result from alterations of the geometry of the left or right ventricle, respectively 10 . In a review published in 2014, mitral regurgitation was secondary in approximately 50% of patients with mitral regurgitation undergoing transcatheter aortic valve implantation (TAVI) 11 . Coronary artery disease and a history of myocardial infarction are highly preva lent in patients with degenerative valve disease, and ischaemic mitral regurgitation is, therefore, common in the ageing population [12] [13] [14] [15] and, therefore, in elderly patients with degenerative valve disease. Aortic root dilatation can cause functional aortic regurgitation with anatomically normal aortic valve cusps 16 . Moreover, primary and secondary aetiologies can coexist.
Despite the prevalence of MVD, limited data exist in the literature to guide the management of patients with this disease. The large number of possible pathophysiological combinations contributes to the scarcity of studies. In this Review, we assess the available data on the pathophysiological complexity of MVD, discuss the diagnostic pitfalls, and consider potential management strategies for these challenging clinical scenarios. We do not examine the specific problems of mixed heart valve disease, that is, the combination of stenosis and regurgitation of the same valve.
Pathophysiology
The clinical effect of MVD depends on a complex interplay of pathophysiological factors, including the severity of each individual valve lesion, which combination of valves are diseased, the type (primary versus secondary) and chronicity of the lesions, loading conditions, and ventricular compensation. The severity and clinical effect of one valve lesion can be altered if loading conditions change or if another valve is repaired. These haemodynamic interactions can promote, exacerbate, or, by contrast, blunt the clinical expression of each singular lesion. For example, in some patients, a rapid decrease in the severity of mitral regurgitation occurs after mechanical correction of aortic stenosis. Similarly, one concomitant valve lesion can modify the clinical effect of another. For example, two patients with equally severe aortic regurgitation might experience the ventricular and clinical consequences of the aortic regurgitation at different time points if one patient has concomitant mitral stenosis (which can protect from the volume load of aortic regurgitation) and the other patient has concomitant mitral regurgitation (which exacerbates the volume load). The complex and dynamic pathophysiology of MVD makes the evaluation, diagnosis, and management of these patients challenging. Although each case of MVD is different and precludes generalization, we review some general pathophysiological principles that should be considered with the following combinations of valve lesions.
Aortic stenosis and mitral regurgitation
Long-standing increased afterload resulting from aortic stenosis leads to hypertrophic remodelling of the left ventricle. However, a substantial proportion of patients with aortic stenosis develop left ventricular (LV) dilatation and systolic dysfunction as a result of LV afterload mismatch, concomitant cardiomyopathy (frequently of ischaemic origin), or both. In turn, LV dilatation and adverse remodelling can be accompanied by secondary mitral regurgitation owing to mitral annular dilatation and leaflet tethering 17 (FIG. 1) . Elderly patients (aged >70 years) with aortic stenosis often also have coronary artery disease, thus explaining the high prevalence of concomitant secondary ischaemic mitral regurgitation in this population 11, 18 . Alternatively, patients with aortic stenosis can have concomitant primary mitral regurgitation. The systolic transmitral pressure gradient is inherently increased in the presence of aortic stenosis and, therefore, the regurgitant flow rate (and the regurgitant volume) will be increased for any given mitral regurgitant orifice area 19 . The presence of moderate or severe mitral regurgitation, whether primary or secondary, can alter the clinical presentation of patients with aortic stenosis. Mitral regurgitation contributes to a low-flow state, resulting in a low transaortic pressure gradient despite a small aortic valve area (FIG. 1) . Atrial fibrillation, which frequently results from mitral valve diseases, can exacerbate the clinical condition, because loss of the atrial kick is poorly tolerated in patients with aortic stenosis. Furthermore, atrial fibrillation is an independent risk factor for heart failure, stroke, and death in patients with aortic stenosis 20, 21 . In addition, aortic stenosis and mitral regurgitation have opposite effects on ejection phase indices of myocardial performance 17 . Therefore, unlike patients with isolated mitral regurgitation, those with aortic stenosis and mitral regurgitation can experience an improvement in LV ejection fraction (LVEF) after mitral valve replacement if the stenotic aortic valve is concomitantly replaced (FIG. 2) . Conversely, the early detection of LV dysfunction in patients with aortic stenosis can be impeded by the presence of mitral regurgitation.
Aortic stenosis and mitral stenosis
The combination of severe aortic and mitral stenosis is infrequent in developed countries, because this condition is usually very poorly tolerated from a haemodynamic standpoint, and treatment is sought early during the course of the disease 22 . When both stenoses are severe, a greater reduction in cardiac output occurs than with just one severe stenosis, decreasing the flow rate and pressure gradients across both valves, which can lead to under estimation of the severity of both aortic and mitral stenosis 23 (FIG. 3) . Whereas physical findings are mainly caused by the aortic stenosis, several clinical manifestations resulting from the mitral stenosis -including atrial fibrillation, haemoptysis, and peripheral embolization -can occur. If concomitant severe aortic stenosis is not recognized 24 , percutaneous balloon mitral valvulo plasty could impose a sudden preload increase to a small, hypertrophied, and stiff left ventricle, resulting in pulmonary oedema 25 .
Key points
• Multivalvular disease (MVD) is a prevalent form of valvular heart disease; rheumatic heart disease is the predominant aetiology in developing countries, whereas degenerative aetiologies are increasingly common in developed countries • Haemodynamic interactions between valve lesions can promote, exacerbate, or, by contrast, blunt the clinical expression of each singular lesion • Several diagnostic tools used for the assessment of valve stenosis or regurgitation have been validated in patients with single-valve disease, but such tools might not be valid for MVD • Therapeutic decisions should be made by a heart valve team, considering the severity of MVD, the patient's life expectancy and comorbidities, and the risks of multiple prostheses and eventual reoperation • The introduction of transcatheter valve therapies is changing the therapeutic paradigm, but further studies are needed to guide therapeutic decision-making
Degenerative (or calcific) mitral stenosis is predominantly found in elderly individuals and is usually the result of progressive mitral annular calcification involving the base of the leaflets. Degenerative mitral stenosis causes progressive reduction in the functional valvular orifice, without commissural fusion 26 . The resulting valvular stenosis is generally less severe than in rheumatic valve disease, thereby decreasing the prevalence of combined critical aortic and mitral stenosis in this population 22 .
Aortic regurgitation and mitral stenosis
The combination of aortic regurgitation and mitral stenosis imposes opposite loading conditions on the left ventricle. Both LV end-diastolic and end-systolic volume are lower than with isolated aortic regurgitation 27 . Therefore, the increase in stroke volume typically associated with aortic regurgitation might be blunted in the presence of mitral stenosis, and the clinical signs associated with increased pulse pressure might not be observed 28 .
Aortic regurgitation and mitral regurgitation
This condition, characterized by severe volume overload caused by the two regurgitations and some pressure overload typically associated with aortic regurgitation, is usually poorly tolerated. LV dilatation can be severe and the pattern of hypertrophic remodelling is eccentric (that is, a low ratio of wall thickness to cavity diameter). Furthermore, premature mitral valve closure -a protective mechanism limiting the amount of backward flow into the left atrium and the pulmonary veins in acute and severe aortic regurgitation -does not occur, which contributes to poor clinical tolerance in patients with concomitant aortic and mitral regurgitation. Patients with this combination of valve lesions who are symptomatic have worse LV performance than those with isolated aortic or mitral regurgitation 29 , resulting in a high incidence of postoperative LV dysfunction 30 . However, over long-term follow-up, LV function can eventually improve 31 . Nonetheless, patients with aortic and mitral regurgitation have significantly reduced postoperative survival and more frequently persistent symptoms after surgery than those with single-valve disease 29 .
Tricuspid regurgitation and left-sided valve disease
Secondary tricuspid regurgitation is highly prevalent in patients presenting with mitral valve disease 32, 33 (FIG. 4) , and is also common in patients undergoing surgical or transcatheter aortic valve replacement for aortic stenosis. Secondary tricuspid regurgitation is associated with reduced postoperative survival 6, 34, 35 . As with secondary mitral regurgitation, a complex interplay of factorsincluding free wall annular dilatation, right ventricular enlargement and dysfunction, pulmonary hypertension, and right atrial enlargement -underlies the presence and severity of secondary tricuspid regurgitation in the setting of left-sided valve disease. However, no single factor is independently associated with secondary tricuspid regurgitation. Importantly, the severity of tricuspid regurgitation is highly sensitive to changes in loading conditions, and the absence of regurgitation at the time of treatment of the left-sided valve lesion does not guaran tee long-term freedom from tricuspid regurgitation (that is, annular dilatation alone can be a harbinger of future tricuspid regurgitation). More studies are needed to elucidate the pathophysiology and determinants of secondary tricuspid regurgitation in the setting of left-sided valve disease and to identify predictors of development or progression of tricuspid regurgitation if the tricuspid valve is not treated.
Diagnosis
The haemodynamic consequences of MVD on blood flow, and on ventricular size, shape, and function, as well as the specific combination of valve lesions can influence the diagnostic process in many ways 9 . Physical examination can be misleading both in terms Figure 1 | Pathophysiology of combined aortic stenosis and mitral regurgitation. Mitral valve deformation and tethering, as well as an increase in transmitral pressure gradient caused by aortic stenosis, all contribute to mitral regurgitation. Increased left ventricular (LV) afterload related to aortic stenosis, combined with mitral regurgitation, result in a decrease in forward LV stroke volume and, therefore, often to a low-flow, low-gradient pattern. Both aortic stenosis and mitral regurgitation can, in the long-term, induce LV myocardial fibrosis and dysfunction. However, the extent of LV systolic dysfunction in such cases is underestimated by LV ejection fraction owing to the LV concentric remodelling related to aortic stenosis and the retrograde flow (mitral regurgitant volume) related to mitral regurgitation. of the timing and intensity of murmurs heard during auscultation, and of other signs such as pulse pressure. Echocardiography is the cornerstone of the diagnosis of valvular heart disease. However, several Doppler methods commonly used for the assessment of stenosis or regurgitation have been validated only in patients with single-valve disease and might not be valid in the setting of MVD. Echocardiographic assessment should include quantification of the stenosis or regurgitation, and evalu ation of valve anatomy and function, integrated in a multiparametric analysis 36 . Left and right ventricular volume and function and pulmonary pressure should also be assessed. As a general rule, measurements that are not dependent on loading conditions, such as direct planimetry of a stenotic valve or, for regurgitant lesions, assessment of the effective regurgitant orifice or the vena contracta, are preferred.
A low-flow, low-gradient stenosis is common in MVD (FIG. 3) . Indeed, any severe valve lesion can reduce flow and, therefore, the gradient across another stenotic valve. A low-flow, low-gradient pattern makes the accurate assessment of stenosis severity difficult. Conversely, the presence of concomitant regurgitation on a stenotic valve (mixed lesion) will have the opposite effect -that is, increase the transvalvular flow and, therefore, the pressure gradient. Mitral valve area should not be evalu ated using the continuity equation method in the presence of aortic regurgitation, because the transmitral flow differs from the transaortic flow. Pressure half-time-derived echocardiographic methods are invalid in the presence of altered LV compliance or relaxation. Therefore, mitral pressure half-time in the presence of aortic valve disease should be interpreted with caution 37, 38 . These and other diagnostic echocardiographic caveats of MVD are summarized in TABLE 1. Aortic or pulmonary valve disease can lead to remodel ling of the left and right ventricles and, therefore, of the respective atrioventricular valve and subvalvular apparatus. In turn, secondary mitral or tricuspid regurgitation can result. In addition, the increased driving pressure across the atrioventricular valve in the presence of aortic or pulmonary stenosis will increase the regurgitant volume. In this context, the regurgitant volume accurately reflects the haemodynamic burden of the regurgitation and correlates with symptoms, but will tend to be disproportionately elevated as compared with the effective regurgitant orifice. Conversely, the effective regurgitant orifice area is more useful to guide decisions about whether to perform concomitant correction of the regurgitation of the atrioventricular valve if the patient undergoes replacement of the aortic or pulmonary valve.
Catheterization is recommended when discordant or inconclusive results are obtained on physical examination and with noninvasive testing 39 . In the EuroHeart Survey, catheterization was performed in 30% of patients with MVD 1 . However, right-heart catheterization cannot be used accurately in this setting because the stroke volume obtained using this technique does not equal the stroke volume across the aortic or the mitral valve in the presence of mixed aortic or mitral valve disease, respectively. In addition, thermodilution can be misleading in the assessment of cardiac output and, therefore, valve area in patients with severe tricuspid regurgitation, very low cardiac output, or both -situations that are common in patients with MVD 40, 41 .
Multimodality imaging
Echocardiography is the primary imaging modality used to establish a diagnosis and monitor patients with MVD, but other imaging modalities can be helpful when the information obtained using echocardiography is not sufficient or is inconclusive to determine the severity of each individual valvular lesion. Determination of the severity of stenotic lesions can be hampered by the frequent occurrence of low-flow states with resulting 'pseudonormal' low gradients or 'pseudosevere' valve stenosis. Nevertheless, an accurate diagnosis is critical, often with implications for treatment decisions. The continuity equation, on which the estimation of aortic valve area is based, assumes a circular shape of the LV outflow tract. However, 3D analysis has demonstrated that the annulus often has an oval shape 42 . Therefore, LV outflow tract area, as measured by 3D echocardiography, MRI, or multidetector CT is often larger than the area calculated from a single LV outflow tract diameter obtained using transthoracic echocardiography 43 . This larger LV outflow tract area will translate into a different (and often larger) aortic valve area when 3D methods are used 44 . However, these measurements of aortic valve area by hybrid methods (for example, LV outflow tract area measured using multislice CT and flow velocities measured using Doppler echocardiography) have Nature Reviews | Cardiology to be used with technique-specific validated thresholds that might be >1 cm 2 (the validated threshold for echocardiography) 45 . Dobutamine stress echocardiography should be performed in patients with low flow and a low transaortic gradient, but a small valve area, to exclude pseudo severe aortic stenosis 46 . In these difficult cases, particularly when the results of echocardiography are inconclusive, multislice CT can be used to assess the aortic valve calcium score (severe stenosis: >2,000 AU in men and >1,200 AU in women) 47, 48 . Real-time 3D transoesophageal echocardiography can be useful to measure mitral valve area in rheumatic mitral stenosis 49 , whereas real-time 3D echocardiography with colour-defined planimetry can be useful in selected patients with degenerative calcified mitral steno sis 50 . However, with the exception of interventional cardiology 51 , the role of multimodality imaging in the setting of MVD is currently limited.
Treatment
Evidence on medical, surgical, and interventional management of patients with MVD is scarce. Most recommendations from both US 39 and European 52 guidelines are, therefore, given a level of evidence C (TABLE 2) . Several factors should, however, be taken into account when determining the optimal management strategy. First, the increased surgical risk of combined procedures and the long-term increase in morbidity associated with multiple prosthetic valves. Second, the risk of eventual reoperation and the prognostic effect of not correcting a less-than-severe lesion. Third, the likelihood of spontaneous changes in mitral or tricuspid regurgitation after surgery on a downstream valvular lesion. Fourth, the choice of surgical technique. Fifth, the emerging role of percutaneous approaches, and sixth, the crucial role of a heart valve team. We consider each of these factors in turn.
Surgical risk and long-term morbidity
Combined surgical procedures on multiple valves are associated with increased operative risk. Among patients with MVD included in the EuroHeart Survey, in-hospital mortality was 6.5%, compared with 0.9% to 3.9% for single-valve surgery 1 . In a series of 513 patients undergoing multiple-valve surgery, in-hospital mortality was 12.5%, and 5-year mortality was 32.9% 53 . Postoperatively, 80% of the patients discharged from hospital improved to NYHA functional class I or II, with only 0.6% remaining in functional class IV. The 5-year rate of freedom from late combined valve-related morbidity and mortality was 71.7% 53 . Pulmonary artery hypertension was one of the main risk factors for postoperative mortality 53 . Among the 623,039 patients undergoing valvular surgery between 1993 and 2007 included in the STS database, 10.9% had multiple-valve procedures 3 . Overall, operative mortality almost doubled compared with single-valve procedures (10.7% versus 5.7%) 3 . However, a higher proportion of patients with NYHA class III/IV congestive heart failure and a higher incidence of nonelective surgery with multiple-valve procedures might have contributed to the increased mortality in these patients 3 .
In this large series, unadjusted operative mortality was 10.7% for the combination of aortic and mitral surgery, 13.2% for aortic plus tricuspid, 9.7% for mitral plus tricuspid, and 14.0% for triple-valve surgery, whereas unadjusted operative mortality was 4.9%, 6.9%, and 10.0% for isolated aortic, mitral, and tricuspid surgery, respectively 3 . Results are improving noticeably over time, with a decrease in mortality between 1993 and 2007, despite worsening in preoperative risk profiles 2 . In another analy sis, risk factors significantly associated with operative mortality included emergency presentation, increasing age, renal failure, reoperation, endocarditis, diabetes mellitus, severe chronic lung disease, peripheral vascular disease, coronary artery disease, and female sex 54 . In a series of 871 patients with rheumatic heart disease undergoing triple-valve surgery, 30-day hospital mortality was 8% 55 . NYHA class IV functional status, ascites, and reduced LVEF were identified as independent risk factors for in-hospital mortality. Overall long-term survival was 71 ± 3% at 5 years, and 59 ± 5% at 10 years, with 74% of surviving patients remaining in NYHA class I or II 55 . Nature Reviews | Cardiology . This case highlights the inaccuracy of the pressure half-time method to assess mitral valve effective area in the presence of severe aortic valve disease. Moreover, this patient exemplifies the frequent and challenging situation of low-flow, low-gradient stenosis, present here at both the aortic and the mitral valves. This situation can lead to underestimation of the severity of aortic and mitral stenoses.
Together, the results from these studies demonstrate that, at the price of an increased operative risk, acceptable clinical improvement and late survival can be expected after a multiple-valve operation. In addition, these data also indicate that the risk of late mortality after multiple-valve surgery can be reduced by early surgical treatment, before pulmonary hypertension, progression to NYHA class IV, or deterioration of LVEF occur.
Risk of reoperation
Treatment decisions for patients with MVD require knowledge of the natural history of each specific valvular lesion. The risk of eventual reoperation and the prognostic implications of not correcting a less-than-severe lesion should also be taken into account. Increased operative mortality and poor long-term survival are to be expected after a 'redo' valve procedure 56 . Patient age and the aetiology of the secondary valve lesion are the main factors influencing operative mortality and longterm survival 56 . Therefore, the likelihood and timing of reoperation for the secondary valve lesion should be considered when planning the initial surgical procedure.
Moderately severe valve lesions have variable rates of progression; some progress in severity more often and more quickly than others. In patients with mild-to-moderate aortic stenosis, the average yearly increase in transaortic velocity and mean gradient is 0.3 m/s and 7 mmHg, respectively, whereas the decrease in valve area is 0.1 cm 2 per year 57 . However, the pattern of progression varies according to its aetiology; aortic stenosis progresses faster in patients with degenerative disease than in those with a rheumatic or congenital aetiology 58, 59 . A higher degree of valvular calcification is independently associated with faster stenosis progression and worse outcome 60 . Aortic regurgitation is slow to progress. Patients with aortic regurgitation and normal LV systolic function who are asymptomatic have a low likelihood of progression to asymptomatic LV systolic dysfunction (<3.5% per year) 61 . The risk of developing symptoms or LV dysfunction is <6.0% per year, and the risk of sudden death <0.2% per year 61 . In a series of 262 patients with moderate aortic regurgitation, the average rate of progression to severe aortic regurgitation was 1.9% per year, and only 0.3% of patients were referred for aortic valve replacement 62 . The rate of mitral valve narrowing in patients with rheumatic mitral stenosis is variable, with an average decline of 0.09 ± 0.21 cm 2 per year 63, 64 . The rate of progression is, however, faster in patients with a greater mitral valve echocardiographic score and higher transmitral gradients.
Most recommendations on the management of lessthan-severe valve lesions in patients undergoing surgery for another valve lesion have been extrapolated from data obtained with CABG surgery. After CABG surgery, the long-term risk of death is more than twofold higher in patients with moderate-to-severe aortic stenosis (aortic valve area 1.0-1.25 cm 2 ) than patients with no aortic stenosis 65 . The available data indicate that, during CABG surgery, concomitant aortic valve replacement for moderate aortic stenosis should be recommended if surgical risk is not prohibitive 66 . The situation is less clear for mild aortic stenosis [67] [68] [69] , but concomitant aortic valve replacement can be considered in patients who are expected to be 'rapid progressors' (that is, those with documented rapid increase in aortic velocity, moderateto-severe valve calcification, or both), providing that reasonable life expectancy is anticipated. Patients with a high surgical risk can be treated conservatively with CABG surgery and a percutaneous valve replacement performed later if necessary.
Risk of mitral or tricuspid regurgitation
Spontaneous changes in mitral or tricuspid regurgitation can occur after surgery on a downstream valvular lesion. The severity of mitral regurgitation can be influenced by the presence of aortic valve disease 11, 17, 70 . After aortic valve replacement, the LV systolic pressure drops, thereby reducing the transmitral pressure gradient. In addition, reverse LV remodelling can be initiated as early as the postoperative period 19 , which contributes to reduced mitral regurgitation (FIG. 2) . However, the mitral valve response to aortic valve replacement is hetero geneous; whereas a favourable response has been described in a substantial number of patients, mitral regurgitation can remain unchanged or even worsen in some patients 11, 13 . Primary mitral regurgitation is less likely than secondary regurgitation to improve after aortic valve replacement 14, 71 . In addition to a secondary aetiology, several factors have been associated with an improvement in the magnitude of mitral regurgitation after aortic valve replacement: poor LVEF and larger LV volumes (indicating a greater potential for reverse remodelling), smaller left atrial size, absence of atrial fibrillation or pulmonary Nature Reviews | Cardiology hypertension (consistent with lesser chronic repercussions of mitral regurgitation), and higher preoperative transaortic pressure gradient and lesser postoperative prosthesis-patient mismatch (consistent with a greater postoperative reduction in systolic transmitral gradient) 11, 17 . In addition, the use of self-expanding valves seems to be associated with less improvement in mitral regurgitation than balloon-expandable valves 72, 73 . This finding might be explained by anatomical or functional interference with mitral leaflet excursion annulus geometry, or by the increased incidence of LV dyssynchrony resulting from left bundle branch block or pacemaker insertion. Balloon aortic valvuloplasty has been shown to reduce the severity of mitral regurgitation in nearly half of patients with severe aortic stenosis and coexistent mitral regurgitation 74 , but no specific data exist to support the routine use of this procedure to select patients who should not receive an additional mitral procedure during aortic valve replacement.
Secondary tricuspid regurgitation is an independent predictor of long-term mortality 6, [32] [33] [34] [35] 75 . Mitral and aortic valve replacement tend to decrease pulmonary vascular pressures and so reduce right ventricular overload; therefore, conservative management of moderate secondary tricuspid regurgitation has been postulated 76 . However, as discussed, the pathophysiological links between left-sided valve disease and secondary tricuspid regurgitation are not linear or predictable. Several studies have demonstrated that the presence of untreated moderate-to-severe tricuspid regurgitation at the time of aortic or mitral valve surgery is associated with reduced postoperative survival 6, 32 . Moreover, late onset of tricuspid regurgitation is associated with poor functional tolerance and reduced exercise capacity 77 . Redo surgery for secondary tricuspid regurgitation is associated with operative mortality of 10-25% 78 . Accordingly, patients with severe secondary tricuspid regurgitation, or those with mild-to-moderate secondary tricuspid regurgitation and evidence of right-sided heart failure or annular dilatation (>40 mm when measured in end-diastole in the four-chamber view, or >70 mm when assessed by a surgeon in the operating room) are generally recommended to undergo tricuspid valve surgery at the time the left-sided valve lesion is fixed 39, 52, 79 (FIGS 4, 5) .
Choice of surgical technique
Whether valve repair or replacement is the optimal surgical strategy should be considered when making management decisions for patients with MVD. In a propensity-matched analysis of patients with aortic and mitral valve lesions, aortic valve replacement and mitral valve repair improved late survival compared with replacement of both valves 80 . Similarly, in another study of patients with rheumatic heart disease, mitral valve repair plus aortic valve replacement improved eventfree survival compared with double-valve replacement 81 . In the STS database, 23,404 patients underwent concomitant aortic valve replacement and mitral valve surgery between 1993 and 2007 (REF. 82 ). Mitral valve repair was performed in 46%, and these patients had a 39% reduction in the risk of operative mortality compared with those undergoing mitral valve replacement, despite them being of older age, with a lower LVEF, and a higher incidence of concomitant CABG surgery 82 . Therefore, efforts should be directed towards improving rates of mitral valve repair, even if prosthetic valve replacement of another valve decrease the willingness of a surgeon to repair the mitral valve.
Controversy exists, however, as to whether repair or replacement of the mitral valve is preferred in patients who have moderate-to-severe secondary mitral regurgitation and are undergoing aortic valve replacement. In one study, reduced in-hospital mortality was reported with mitral valve repair (11% versus 18% for replacement), but survival after discharge from hospital did not differ signifi cantly between the two strategies 83 . Conversely, other studies that included patients with primary or secondary mitral regurgitation reported no survival benefit of mitral valve repair with aortic valve replacement over double-valve replacement, and an increased long-term incidence of mitral valve failure in patients undergoing mitral repair was observed 84, 85 . In a propensity matched analysis 86 and in the Cardiothoracic Surgery Network randomized trial 87 , mitral valve replacement was associated with better freedom from recurrent secondary ischaemic mitral regurgitation during follow-up compared with mitral valve repair.
When a patient is to undergo double-valve replacement, using the same type of prosthesis in both locations (bioprosthesis or mechanical) has been recommended so as not to lose the advantages of each valvular option. That is, to avoid superimposing the risk of anticoagulation and the risk of bioprosthesis deterioration 7 . No data are available on which type of valve prosthesis is preferable. 52 
Aortic stenosis
• AVR is indicated for patients with severe aortic stenosis undergoing other cardiac surgery (class I, LOE B) • AVR is reasonable for patients with moderate aortic stenosis undergoing other cardiac surgery (class IIa, LOE C)
• AVR is indicated in patients with severe aortic stenosis undergoing CABG surgery, or surgery on the ascending aorta or another valve (class I, LOE C) • AVR should be considered in patients with moderate aortic stenosis undergoing surgery on the ascending aorta or another valve (class IIa, LOE C)
Aortic regurgitation Tricuspid annuloplasty is the preferred technique for the surgical treatment of tricuspid regurgitation at the time of left-sided valve surgery, because tricuspid regurgitation is usually the result of annulus dilatation with ensuing lack of leaflet coaptation. Moreover, tricuspid annuloplasty valve replacement is associated with a lower rate of complications than tricuspid valve replacement 33, 78, 88, 89 .
Percutaneous approaches
Percutaneous treatment of aortic stenosis and mitral regurgitation is increasingly used in patients at high surgical risk. Limited series of combined transcatheter treatment of aortic stenosis and mitral regurgitation have been reported 90, 91 . In carefully selected patients, a staged approach has been proposed -the valve steno sis is treated first by TAVI, followed by subsequent implantation of a MitraClip ® (Evalve, Inc., USA) if moderateto-severe mitral regurgitation with symptoms persists. This strategy has been associated with good procedural success rates and, at 6 months, acceptable functional outcomes and survival 91 .
In patients with severe aortic stenosis undergoing TAVI, the concomitant mitral stenosis is generally of degenerative aetiology (that is, mitral annulus calcification) with significant thickening and calcification of the subvalvular apparatus, and absence of commissural fusion, and is, therefore, not suitable for percutaneous mitral commissurotomy 92 . However, in exceptional circumstances, circular mitral annular calcification is severe enough to cause haemo dynamically significant mitral stenosis and can offer enough support to allow stable anchoring of a percutaneous mitral prosthesis 93, 94 .
In the past 5 years, several percutaneous procedures have been developed and successfully used to treat secondary tricuspid regurgitation 88, 95 . These emerging techniques provide a valuable alternative to surgery to correct tricuspid regurgitation at the time of other percutaneous intervention on the aortic or mitral valve, or as a staged procedure after surgical or percutaneous treatment of another valve. More studies are needed to clarify these treatment pathways and to incorporate evolving transcatheter options for mitral valve replacement and tricuspid repair.
The heart valve team
The evaluation and treatment of patients with MVD can be incredibly complex. The numerous diagnostic pitfalls, emergence of innovative transcatheter therapies, and treatment of elderly high-risk patients with multiple comorbidities require the expertise of a multi disciplinary heart valve team
. Expertise in cardiac surgery, trans catheter interventions, cardiac imaging, haemo dynamics, anaesthesia, and geriatrics is critical to making the best recommendations and tailor ing treatment strategies to optimize outcomes for individual patients 96 .
Clinical scenarios
Three main clinical scenarios are encountered in clinical practice -patients with two or more severe lesions, patients with one severe lesion plus at least one nonsevere lesion, and patients with two or more nonsevere lesions. The recommendations for concomitant valve surgery in patients undergoing surgery on another valve, as outlined in the AHA/ACC 39 and ESC/EACTS 52 guidelines, are presented in 
Two or more severe lesions
The general recommendation for patients with two or more severely stenotic or regurgitant lesions, and who are symptomatic or have ventricular dysfunction or dilatation, is for all lesions to be surgically corrected concomitantly 39, 52 . However, for patients at high or prohibitive risk of surgery, alternative treatment pathways have been proposed. In such cases, the staged percutaneous approach involving the MitraClip ® outlined above might be considered. This rapidly evolving area will become only more complex with the emergence of transcatheter options for tricuspid disease.
One severe lesion plus at least one nonsevere lesion The decision to perform an intervention should be based on the recommendations for the predominant valvular lesion 52 . Whether an additional procedure on a coexistent nonsevere valvular lesion is required can be difficult to determine. The surgical risk of a combined valve procedure and the long-term increase in morbidity associated with multiple valve prostheses should be balanced against the risk of eventual reoperation and the prognostic implications of not correcting the less-severe lesion during the initial procedure. In addition, life expectancy, comorbidities, and patient wishes should all be taken into account.
In the current AHA/ACC 39 39 . In patients with one severe and one moderatelysevere valve lesion who are asymptomatic, the increased operative risk associated with a double-valve procedure is an incentive to postpone surgery until symptoms develop or another class I indication for surgery exists. Decisional algorithms for patients with aortic stenosis presenting with concomitant mitral regurgitation have been proposed. These algorithms take into account the severity and mechanism of mitral regurgitation, the likelihood of spontaneous improvement if isolated aortic valve replacement is performed, as well as the individual surgical risk 11, 17 (FIG. 5) . In patients with severe mitral stenosis and concomitant moderate aortic valve disease, percutaneous mitral commissuro tomy can be performed to postpone double-valve surgery. Indeed, only a minority of these patients will require subsequent aortic valve replacement on long-term follow-up, emphasizing the limited progression of aortic regurgitation in this setting 97 . 39, 52 . Importantly, in some elderly patients, performing an intervention to improve quality of life can be more important than prolonging life. Procedures that are bene ficial only after a long period of survival might be less suitable or appropriate for very elderly patients. Single-valve procedures that are less demanding and carry a lower risk than double-valve or triple-valve procedures should be considered for these individuals, even at the cost of incomplete repair. Two or more nonsevere lesions In patients with nonsevere MVD, determining the global consequences of all lesions is of the utmost importance. Even moderate lesions, when combined, can lead to severe functional intolerance, symptoms, LV dilatation or dysfunction, and pulmonary hypertension. This combination of lesions is the most challenging in terms of therapeutic decision-making. The consequences of the overall haemodynamic burden on the cardiac chambers, pulmonary circulation, and patient's functional cap acity should be assessed. Therefore, maximal exercise cap acity and peak oxygen consumption, parameters of ventri cular function (such as LV global longitudinal strain, RV tricuspid annulus plane excursion, or free-wall strain), as well as natriuretic peptide levels and pulmonary arterial pressure at rest and during exercise should be measured 98, 99 . Surgery might be appropriate for selected patients in whom the combination of moderate lesions has a meaningful effect on the functional parameters mentioned above. However, further studies are needed to identify and validate criteria for intervention in this subset of patients.
Conclusions
Degenerative aetiologies have replaced rheumatic heart disease as the predominant causes of MVD, the prevalence of which is increasing in developed countries owing to ageing of the population. Clinicians must be aware of specific pitfalls associated with the evaluation of MVD; diagnosis and treatment of this condition depend on the individual patient's presentation and combination of valve pathologies. Patient-centred therapeutic decisions should be made by a multidisciplinary heart valve team, with integration of numerous factors to optimize clinical outcomes. Much work remains to be done to develop evidence to guide treatment decisions for these complex clinical cases. Several randomized trials are currently ongoing to assess the benefit of performing concomitant tricuspid annuloplasty at the time of mitral valve surgery in patients with mild or moderate tricuspid regurgitation. Similar studies will also be needed for patients undergoing aortic valve surgery. Randomized trials are also needed to determine whether concomitant treatment of moderate mitral regurgitation at the time of surgical or percutaneous aortic valve procedure improve patient outcomes.
